Combination Antiplatelet Therapy for Secondary Stroke Prevention: Enhanced Efficacy or Double Trouble?

American Journal of Cardiology

Volumn 103, Issue 8, 2009, Pages 1107-1112

  Usman, M Haris U ^a,b   Notaro, Lawrence A ^a   Nagarakanti, Rangadham ^a   Brahin, Eric ^b   Dessain, Scott ^a,c   Gracely, Edward ^d   Ezekowitz, Michael D ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; PHENPROCOUMON; PLACEBO; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTICOAGULANTS; ASPIRIN; DIPYRIDAMOLE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 63749112292     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.003     Document Type: Review

References (39)

1. Mueller R.L., and Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 89 (1994) 432-449
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
3. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., Teal P., and American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008) 630S-669S
4. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
5. Boysen G. Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. J Intern Med 246 (1999) 239-245
6. Serebruany V.L., Malinin A.I., Eisert R.M., and Sane D.C. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 75 (2004) 40-47
7. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Baggish J.S., Bhatt D.L., and Topol E.J. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
8. Mohr J.P., Thompson J.L., Lazar R.M., Levin B., Sacco R.L., Furie K.L., Kistler J.P., Albers G.W., Pettigrew L.C., Adams Jr. H.P., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001) 1444-1451
9. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338 (1991) 1345-1349
10. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Pfeffer M., Hohnloser S., and Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
11. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 348 (1996) 1329-1339
12. Chimowitz M.I., Lynn M.J., Howlett-Smith H., Stern B.J., Hertzberg V.S., Frankel M.R., Levine S.R., Chaturvedi S., Kasner S.E., Benesch C.G., et al., Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005) 1305-1316
13. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J., and MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
14. Farrell B., Godwin J., Richards S., and Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
15. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
16. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
17. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325 (1991) 1261-1266
18. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A., and ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 6 (2007) 115-124
19. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., and Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
20. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., Palesch Y., Martin R.H., Albers G.W., Bath P., et al., PROFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008) 1238-1251
21. Tong D.C., Adami A., Moseley M.E., and Marks M.P. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging. Arch Neurol 58 (2001) 587-593
22. Boulanger J.M., Coutts S.B., Eliasziw M., Gagnon A.J., Simon J.E., Subramaniam S., Sohn C.H., Scott J., Demchuk A.M., and VISION Study Group. Cerebral microhemorrhages predict new disabling or fatal strokes in patients with acute ischemic stroke or transient ischemic attack. Stroke 37 (2006) 911-914
23. Dalen J.E. Aspirin to prevent heart attack and stroke: what's the right dose?. Am J Med 119 (2006) 198-202
24. Campbell C.L., Smyth S., Montalescot G., and Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007) 2018-2024
25. Hanley S.P., Bevan J., Cockbill S.R., and Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 1 (1981) 969-971
26. Montalescot G., Maclouf J., Drobinski G., Salloum J., Grosgogeat Y., and Thomas D. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 24 (1994) 33-38
27. Forster W., and Parratt J.R. The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low?. Cardiovasc Drugs Ther 10 (1997) 727-734
28. Quinn M.J., and Fitzgerald D.J. Ticlopidine and clopidogrel. Circulation 100 (1999) 1667-1672
29. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
30. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
31. Aktas B., Utz A., Hoenig-Liedl P., Walter U., and Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 34 (2003) 764-769
32. Lenz T.L., and Hilleman D.E. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 34 (2000) 1283-1290
33. Radomski M.W., Rees D.D., Dutra A., and Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 107 (1992) 745-749
34. Garg U.C., and Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83 (1989) 1774-1777
35. Tsao P.S., Buitrago R., Chan J.R., and Cooke J.P. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 94 (1996) 1682-1689
36. Serebruany V.L., Malinin A.I., Ferguson J.J., Vahabi J., Atar D., and Hennekens C.H. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 22 (2008) 315-321
37. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., and Terrin M.L. Thrombolysis In Myocardial Infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 (1988) 1-11
38. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
39. Serebruany V.L., and Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 99 (2007) 288-290